Venus Medtech Announces Completion of Patient Enrollment in Pivotal China Trial for Venus-PowerX, the World's First Fully Recoverable Self-Expanding Dry-Valve TAVR System

Trial StartpositiveVenus-PowerXPositive

AI Analysis

Summary

Venus Medtech announced completion of patient enrollment in the PREVAILS pivotal study for Venus-PowerX, a next-generation fully recoverable self-expanding dry-valve TAVR system. The completed trial marks progress toward simultaneous regulatory submissions in China and Europe.

Clinical Trial Data

Outcome Details

PREVAILS study patient enrollment completed

Importance:6/10

Sentiment:

0.70

TAVRmedical deviceclinical trialChina regulatoryEurope regulatoryenrollment completion

Related Companies

$VERO

Read the original article

Published by PR Newswire Pharma on July 23, 2026 6:00 AM

Read Original